ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study

• Sponsor: University College, London (Other)
• Overall Status: Completed
• CT.gov ID: NCT02047708
• Collaborator: Medical Research Council (Other)
• Enrollment: 27
• Location: 1
• Duration (Months): 36
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

Many patients with scleroderma have damage to their kidneys caused by the disease. There is limited evidence for treatments to prevent this damage or stop it progressing. Blocking a substance in the blood called endothelin has helped treat some aspects of scleroderma. The purpose of this study is to see how effective a new endothelin blocker called Zibotentan is in treating patients who have scleroderma and have gone on to develop reduced kidney function as a complication. It will be given in addition to the accepted treatments used for scleroderma. There will be three parts to this study each for a different group of patients:

• ZEBRA 1 for patients with mild or moderate kidney disease caused by scleroderma

• ZEBRA 2A for patients with a more severe, acute form of kidney disease caused by scleroderma (scleroderma renal crisis) who do not require dialysis

• ZEBRA 2B for patients who have had scleroderma renal crisis and are on dialysis

Condition or Disease	Intervention/Treatment	Phase
Scleroderma; Scleroderma Renal Crisis; Chronic Kidney Disease	Drug: Zibotentan	Phase 2

Detailed Description

This is a 3-part study (Zebra 1, 2A and 2B) that will explore safety and therapeutic potential of Zibotentan in acute and chronic renal complications of Scleroderma. Trial duration will be 52 weeks for Zebra 1 and 2A (1 or 2 weeks for ZEBRA 2B with 1 year follow up data). Scleroderma (Systemic sclerosis) is a multisystem rheumatic disease that results in vascular damage and fibrosis of target organs.This project will focus specifically on the evaluation and treatment of renal disease in scleroderma.

Renal involvement in Scleroderma occurs with a variety of different pathologies; hypertensive scleroderma renal crisis (SRC) being the most dramatic manifestation but milder forms of chronic renal disease are frequent and represent an important clinical feature.

Study Design

• Study Type: Interventional
• Actual Enrollment: 27 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma
• Study Start Date: Oct 1, 2014
• Actual Primary Completion Date: Oct 1, 2017
• Actual Study Completion Date: Oct 1, 2017

Outcome Measures

Primary Outcome Measures

1. sVCAM 1 soluble Vascular Cell Adhesion Molecule [12 months]

   sVCAM1 is a biomarker of renal involvement in scleroderma

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Adults with scleroderma and:

2. CKD 2/3 (ZEBRA 1)

3. Renal crisis not on dialysis (ZEBRA 2A)

4. Renal crisis on dialysis (ZEBRA 2B)

Exclusion Criteria:

1. Previous use of an endothelin receptor antagonist within 3 months of the study start

2. Significant abnormalities in liver function testing (ALT, ALP, Bilirubin) more than three times upper limit of normal)

3. Patients with body weight <40kg.

4. Patients with conditions which prevent compliance with the protocol or failure to adhere to therapy.

5. Patients with any other life threatening condition.

6. Patients with known hypersensitivity to Zibotentan or its excipients

7. Previous history of epilepsy or other CNS AEs, neurologic symptoms or signs consistent with acute or evolving spinal cord compression, and CNS metastases

8. Patients with a baseline left ventricular ejection fraction < 40% (prior to any scleroderma renal crisis), patients with acute myocardial infarction within six months or patients who are judged by the trial clinician to be at unacceptable risk from cardiac complications.

9. History of chronic alcohol or drug abuse or any condition associated with poor compliance as judged by the investigator

10. Patients receiving cyclosporin A within 1 week of screening or expecting to receive this agent during the study.

11. Patients who have received an investigational agent in the month prior to screening. These patients may be eligible if after a month of washout period, they are still within 112 months of the onset of the Scleroderma renal crisis.

12. Active malignancy or neoplastic disease in the previous 12 months

13. Women who rely on oestrogencontaining contraceptives (due to potential drug interaction with Zibotentan).

14. Females who are pregnant or breastfeeding.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Royal Free London NHS Foundation Trust	London		United Kingdom	NW32QG

Sponsors and Collaborators

• University College, London
• Medical Research Council

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University College, London
• ClinicalTrials.gov Identifier: NCT02047708
• Other Study ID Numbers: 2013-003200-39
• First Posted: Jan 28, 2014
• Last Update Posted: Oct 31, 2017
• Last Verified: Oct 1, 2017

• Additional relevant MeSH terms: Kidney Diseases; Renal Insufficiency, Chronic; Scleroderma, Systemic; Scleroderma, Diffuse; Scleroderma, Localized

Study Results

No Results Posted as of Oct 31, 2017